Accelmed, Peregrine Ventures pump up NLT Spine's funding to $14.5M

Back problems are common afflictions, and many people require surgery to alleviate their suffering. One Israeli company has just received a cash infusion to advance its line of minimally invasive products and make a bigger splash on the U.S. market.

NLT Spine is developing minimally invasive spine surgery products. It has already aroused the interest of Accelmed and Peregrine Ventures, which have driven up the company's funding to $14.5 million as it looks to expand its presence in the U.S.

Minimally invasive spinal surgery is becoming evermore popular, as people seek to experience less postoperative discomfort. NLT is looking to capitalize on this trend.

NLT's products are based on its non-linear core technology, which allows the insertion of large implants and instruments through a small incision. It plans to officially launch its PROW LIF line and additional products next year. It already has experienced some success in the U.S.: The PROW Fusion has recently received 510(k) clearance and is available under limited release.

- get the NLT release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.